tiprankstipranks
pc:ather

Athernal Bio

Athernal Bio is a biotechnology company focused on developing targeted immunotherapies for high-risk clonal haematopoiesis (CH), a prevalent precursor condition to blood cancers such as acute myeloid leukaemia. The company aims to shift oncology treatment from reactive to proactive by preventing cancer development in high-risk patient populations, including those with inherited blood disorders, cancer survivors, and the elderly. Athernal Bio's initial program targets aggressive forms of CH, with the goal of providing early intervention to stop cancer before it starts.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$4M
Total Amount Raised$4M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$4M
Latest Funding Amount$4M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Oct 08, 2025
Investment
$3.50M

Investors

Investor Name
Funding Round
Investment

Related News and Analysis